BNTX:NASDAQ
BioNTech SE - ADR
US$ ९६.५१
arrow_downward
-०.४०%(-०.३९) 1D
अक्टोबर ५, ११:४९:११ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
US$ ९६.७४
High
US$ ९६.८७
Low
US$ ९५.२०
Mkt. cap
२४.२४ अरब
Avg. vol.
१०.९५ लाख
Volume
२.१९ लाख
52-wk high
US$ १२३.९८
52-wk low
US$ ७९.५२
EPS
-US$ ७.५५
Beta
१.२२
Shares outstanding
२५.१२ करोड
No. of employees
८ हजार
Open
US$ ९६.७४
High
US$ ९६.८७
Low
US$ ९५.२०
Mkt. cap
२४.२४ अरब
Avg. vol.
१०.९५ लाख
Volume
२.१९ लाख
52-wk high
US$ १२३.९८
52-wk low
US$ ७९.५२
EPS
-US$ ७.५५
Beta
१.२२
Shares outstanding
२५.१२ करोड
No. of employees
८ हजार
News stories
From web sources and news partners
AD HOC NEWS
·
४ घण्टा पहिले
BioNTech CEO Offloads 100,000 Shares as Founders' Exit Talks Turn Testy
AD HOC NEWS
·
८ घण्टा पहिले
Berenberg raises target for BioNTech stock from USD 132 to USD 140
AD HOC NEWS
·
१ दिन पहिले
BioNTech stock faces a 59.5 percent Q2 revenue drop
Seeking Alpha
·
१ दिन पहिले
BioNTech SE: Moving Past Covid (NASDAQ:BNTX)
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR